PMS29 CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
May 1, 2010, 00:00
10.1016/S1098-3015(10)72617-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)72617-6/fulltext
Title :
PMS29 CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72617-6&doi=10.1016/S1098-3015(10)72617-6
First page :
Section Title :
Open access? :
No
Section Order :
164